We estimated the incremental (extra) direct medical costs of a population-based cohort of newly diagnosed systemic lupus erythematosus (SLE) for five years before and after diagnosis, and the impact of sex and socioeconomic status (SES) on pre-index costs for SLE. Methods: We identified all adults newly diagnosed with SLE over 2001-2010 in British Columbia, Canada, and obtained a sample of non-SLE individuals from the general population, matched on sex, age, and calendar-year of study entry. We captured costs for all outpatient encounters, hospitalisations, and dispensed medications each year.
Introduction
According to a recent systematic review, 1 about three of every 100,000 North Americans are diagnosed with systemic lupus erythematosus (SLE) each year, and up to six per 100,000 Europeans. This disease tends to start slowly and insidiously, with SLE-associated autoantibodies present many years 2, 3 before symptom onset or diagnosis. Though complete SLE is characterised by intense inflammation, organ damage, and a high comorbidity burden, the early manifestations are often non-specific, typically involving arthritis 4, 5 and photosensitivity, 4 which makes diagnosis difficult.
The time from initial symptoms to formal diagnosis (accumulation of four American College of Rheumatology (ACR) Classification Criteria 6 ) spans, on average, two years, 7 but can be longer without the classic malar rash or symptoms suggestive of life-threatening organ involvement. 5 During this time, however, the inflammatory effects of SLE are already setting in. Evidence suggests there is an elevated risk of cardiovascular disease 8 during this period and, by the time of diagnosis, many patients already have renal disease, 9, 10 including nephritis. 11, 12 The investigation of initial symptoms and management of serious health events preceding diagnosis is likely associated with additional medical costs. However, while several estimates are available on the costs of SLE patients following diagnosis, [13] [14] [15] little is known about the years prior. Two recent analyses of primary care data in the United Kingdom (UK) reported substantial increases (65% 16 and 71% 17 ) in primary care visits between the second and first year prior to SLE diagnosis. In the only report we could find on healthcare costs before diagnosis, which described the pre-diagnosis (pre-index) cost patterns in Taiwan, 18 mean perperson costs for outpatient care more than doubled from the fifth to first year before diagnosis. Unfortunately, that study did not assess hospitalisation or medication costs, and their findings may not be generalisable to other countries or healthcare systems. Moreover, the impact of factors like socioeconomic status (SES) and sex on pre-index costs is also unknown. These are of interest since lower SES has been associated with reduced access to care and poorer outcomes 19 later on in the disease course, and males tend to accrue damage more quickly than females. 20 Knowledge of the pre-index healthcare utilisation and costs of SLE patients across multiple settings, not just primary care, would give policymakers more information about the real burden of this disease. It would also inform emerging strategies to expedite diagnosis and initiation of treatment, and even slow 21 or prevent the development of complete SLE in those at high risk, 22 with pre-emptive hydroxychloroquine (HCQ) therapy.
To generate such knowledge, we used routinely collected administrative healthcare data from a single-payer setting capturing the entire population to estimate the incremental healthcare burden of SLE in the five years before diagnosis, and year following, and assess the impact of sex and SES on costs.
Methods

Data source
The province of British Columbia (BC), Canada, has a publicly funded, universal healthcare system through which all legal residents receive medically necessary outpatient and hospital care. The administrative data were sourced through Population Data BC, which uses population-based linkable administrative data files to capture records of all provincially funded healthcare services, including all outpatient medical visits, interventions, and investigations, 23 and hospitalisations 24 from 1990 through 2013, as well as demographic 25 and vital statistics data. 26 Furthermore, it includes data on nearly all community-dispensed prescription medications for all BC residents (population of 3.5 million adults in year 2010), regardless of age or funding source, from 1996 through 2013. 27 Numerous general population-based studies have been successfully conducted using these databases. [28] [29] [30] Ethics approval was obtained from the Behavioral Research Ethics Board at The University of British Columbia (H12-03093). As this was an analysis of de-identified data, participant consent was not required.
Study populations
From the administrative data files, we assembled a population-based cohort of all BC adults (aged ! 18 years) newly diagnosed with SLE from 1 January 2001 through 31 December 2010. SLE cases were identified using International Classification of Diseases Ninth/Tenth (ICD-9/10) Revision diagnostic codes (710.0/M32) recorded for outpatient encounters and hospitalisations as follows: (a) ! two ICD-9 codes for SLE ! two months apart but within a two-year period by a non-rheumatologist physician (excluding codes recorded for laboratory tests and other diagnostic encounters); or (b) one ICD-9 code by a rheumatologist; or (c) one ICD-9/10 code from a hospitalisation. The code could have been in any of the five diagnostic positions in the outpatient billing data or in any of the up to 25 positions in the hospitalisation data. The first SLE-coded encounter was considered the index date. Potential cases were excluded if they had at least two visits ! two months apart (subsequent to the SLE index encounter) with diagnoses of other inflammatory arthritides, including rheumatoid arthritis, psoriatic arthritis, and spondyloarthropathies. The validity of this case definition has been evaluated in another Canadian province with reported sensitivity of 85% and specificity of 98%. 31 The non-SLE group was selected from a random sample of the BC population whom we randomly assigned an index date among all possible dates within the study period. Those whose random date fell outside of their actual follow-up (i.e. after their death) were eliminated. From this pool, we selected up to five individuals per SLE case, matched on age ( AE two years), sex, and calendaryear of study entry, and eliminated any with an SLE diagnosis.
Healthcare utilisation and costs
To ensure only incident cases were included, all individuals (SLE and non-SLE) needed at least five years of registration in the databases prior to meeting the case definition for SLE. This 'run-in' period also ensured we had complete healthcare utilisation and cost data for the preceding five years. Thus, all healthcare utilisations captured in the databases from five years prior to index date and for up to five years after index date (or until the earliest of death, de-registration from BC's universal health insurance provider, or 31 December 2013) were included, and unit costs summed. Though this article focusses on the pre-index period, costs were computed from Year -5 (fifth year before diagnosis) through Year þ 5 (fifth year after diagnosis) to provide evidence on the change in costs after diagnosis. Costs were computed in accordance with guidelines issued by Canada's health technology assessment agency, the Canadian Agency for Drugs and Technologies in Health. 32 The unit cost of each outpatient encounter (available in the dataset) was the amount paid to healthcare providers by the BC Ministry of Health. The costs for each prescription (also available in the dataset) included the complete drug cost and dispensing fee. Costs for inpatient and day hospitalisations were calculated using the Canadian Institute for Health Information (CIHI)'s wellestablished case-mix methodology, 32 in which the resource intensity weight (RIW) of each hospitalisation (provided by CIHI), the relative resource consumption of that particular hospitalisation in relation to the provincial 'standard' (for which the RIW would equal 1.0), is multiplied by the cost of a standard hospital stay in the province each year. All costs were adjusted for inflation using the general component of the Canadian Consumer Price Index. Costs are reported primarily in 2013 Canadian dollars, though for comparison purposes, we also show some estimates converted to 2013 Euros (C$1 ¼ E1.3681) and United States (US) dollars (C$1 ¼ US$1.0299148), using exchange rates from the Bank of Canada.
Independent variables
A modified version of the Charlson-Romano comorbidity index for administrative data, 33 one excluding diagnoses of SLE and other systemic autoimmune rheumatic diseases, was calculated for each 365-day period before index date, and collapsed into categories of 0 or ! 1. For example, when assessing costs incurred during the final 365 days before SLE diagnosis (Year -1), we adjusted for comorbidities recorded during the second 365-day period before diagnosis (Year -2).
SES was defined using Statistics Canada neighbourhood income quintile data, as per previous analyses. 29, 30 SES was grouped according to the income quintile of the address recorded for each individual (by the provincial medical plan) in each study year. Urban/rural residence was defined using the first three digits of the postal code of this address (second digit of 0 indicating a rural address).
Statistical analysis
Unadjusted comparisons between SLE and non-SLE individuals (and between male and female SLE) were made using chi-squared tests and t tests. Mean per-person healthcare use and costs for each year (365-day period) were then determined for the (pre)-SLE and non-SLE cohorts. Multivariable generalised linear models (GLM), adjusted for sex, age at index year, and year-specific comorbidity score, urban/rural residence, and SES, were then used to determine the relative utilisation and costs associated with SLE each year. Negative binomial count models were used to compare volumes of outpatient encounters and dispensed medications. Log-link and gamma distribution were specified in the cost models to account for skewness in these data. 34 The unit of analysis was person-year of followup. Thus, separate regression models were constructed for each year before diagnosis/index date and the year after. Pre-index follow-up time was the same for all individuals (five full years), but postindex follow-up time could be less than one year for some individuals who might have died or reached the end of the study period. To account for this, an offset variable (log of each person's follow-up time) was used in the count models, while the post-index cost models included only individuals followed for the entire post-index year. As some individuals did not incur healthcare costs during each follow-up year, two-part models 34 were used for cost calculation. The first part (a logistic regression model) assessed one's probability of incurring any healthcare costs that year, controlling for covariates, while the second part (a gamma GLM) assessed costs only among those with non-zero costs. Similar models assessed the impact of sex and SES on costs within the SLE cohort.
To derive the incremental costs, which is the difference in costs between the SLE and the comparison group from the two-part model, we used Gcomputation, 35 as has been applied previously on these data. 30 With this approach, multivariable regression models are used to predict costs for each individual multiple times, each time with the same person in a different disease or sociodemographic group, but with their other covariates the same. The difference between estimates (i.e. predicted costs as if the same person did and did not have SLE) represented the incremental costs when the status of the variable changed (i.e. an individual was in the non-SLE or the SLE group), and perperson incremental costs were averaged across all individuals followed each year, with 95% credible intervals derived through parametric bootstrapping. Analyses were generated using the SAS Enterprise software package, version 7.13.
Results
We identified 3632 newly diagnosed SLE patients for the years 2001-2010 (86% female, mean age 49.6 AE 15.9) and 18,060 non-SLE individuals (mean age 49.8 AE 15.4). Two-thirds of SLE cases were diagnosed by a rheumatologist on an outpatient basis, with an additional 20% diagnosed in hospital (Table 1) . SLE males were slightly older, on average, than SLE females (49.1 vs. 52.9 years, p < 0.01), as were non-SLE males and females, and males had a higher comorbidity score at diagnosis. Otherwise, males and females were nearly identical with regards to urban/rural residence, SES distribution, and source of SLE diagnosis.
Costs for SLE in first year after diagnosis (Year þ 1) averaged C$12,019 per person (2013 Canadian; approximately E16,443 or US$12,378) with 58% from hospitalisations, 24% outpatient, and 18% from prescription medications. Mean per-person costs for non-SLE were about five-fold lower, C$2412 per person (E3300; $2484 USD). In the five years leading up to diagnosis, the average year-over-year increase in costs was 35% for the SLE cohort and 7% for non-SLE. However, the largest annual increases for SLE were observed in the final two years before diagnosis: 39% and 97%, respectively (Table 2) . After adjustment for sex, age, urban/rural residence, SES, and comorbidity burden in the preceding year, costs were significantly greater for SLE than non-SLE each year (Table 3) . Incremental costs of SLE (difference in costs between SLE and non-SLE, controlling for covariates) rose over time from C$1131 in Year -5 (E1547; US$1165) to C$1536 in Year -3 (E2101; US$1582), C$3473 in Year -1 (E4751; US$3577) and C$6474 (E8857; US$6668) in the year after SLE diagnosis (Table 2 ).
Healthcare components
During the final two years before diagnosis, costs for outpatient consultations and investigations rose by 39% and 35%, respectively (Figure 1 ). For outpatient investigations specifically, the biggest increase occurred between Years -2 and -1 (by 47%, from C$468 to C$690 per person; equal to E640-944 and US$482-711). Prescription medication costs increased the most (by 33%) between Years -1 and þ1. The percentage of SLE with an inpatient hospitalisation was 10% to 12% in Years À5 to À2, 18% in the year before diagnosis, and 31% the year after, while only 6% to 7% of non-SLE individuals were hospitalised each year. Day hospitalisations accounted for just 2% to 4% of annual costs. 
C$12,019 C$2412 C$9607 C$6474 (C$3220-C$15,437)
a Determined using two-part models: a logistic regression model for the odds of incurring non-zero costs, and generalised linear model with gamma distribution and log-link predicting costs for those with nonzero costs; adjusted for age, sex, previous year's modified Charlson comorbidity score, urban/rural residence and neighbourhood socioeconomic status. SLE: systemic lupus erythematosus; 95% CI: 95% confidence interval.
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Impact of sex
Starting from Year -4, unadjusted annual mean per-person costs for SLE males were about 25% greater than SLE females (Figure 2 ). In the year after SLE diagnosis, their costs were 68% greater (C$18,433 vs. C$10,945) (E25,218 vs. E14,974; US$18,984 vs US$11,272). Following adjustment, male sex was associated with significantly greater costs among SLE in Years -2, -1, and þ1 (Table 4) . Hospitalisations were a major contributor, with males having greater odds of hospitalisation than females in the year before diagnosis (odds ratio (OR) ¼ 1.49, 95% confidence interval (CI) ¼ 1.19-1.88), and significantly greater hospitalisation costs the year after. Conversely, among non-SLE, male sex was associated with significantly lower costs over Years -5 to þ 1. In absolute terms, predicted incremental costs for SLE males (over and above SLE females') were C$540 per person in Year -2 (E739; US$556), C$1385 in Year -1 (E1895; US$1426), and C$2288 in Year þ 1 (E3130; US$2356).
Impact of SES
Among SLE, being in the lowest SES group was associated with significantly greater healthcare costs in Years -4, -2, -1, and þ1 ( Table 4 ). The second-lowest group also had significantly greater costs in Years -2 and þ1. Outpatient costs contributed, but hospitalisations were the major driver in Year þ1. The lowest SES had greater odds of being diagnosed in hospital (OR ¼ 1.45, 1.12-1.88), and, as compared to others diagnosed in hospital, incurred greater costs for this index hospitalisation (adjusted cost ratio ¼ 1.33, 1.05-1.68).
Discussion
To the best of our knowledge, these are the firstknown estimates of outpatient, hospitalisation, and medication costs before SLE diagnosis. With access to routinely collected healthcare utilisation data for virtually all residents of our jurisdiction, we assessed the incremental costs among 3632 SLE patients before and after diagnosis. Though index-year costs were nearly four times greater for SLE than the non-SLE group, SLE patients had significantly greater costs for all of these components, during each of the five years before diagnosis.
The largest increases in utilisation and costs occurred in the two years before diagnosis, which is consistent with the oft-reported span of two years, on average, from symptom onset to SLE diagnosis. 7 However, individuals with SLE also incurred greater costs than non-SLE in the third, fourth, and fifth years before diagnosis, and had more comorbidities recorded in the pre-index period. These findings suggest the rise in incremental costs over time is not solely from consultations and investigations involved in confirming the diagnosis, and rather indicate the broader, systemic aspect of inflammation affecting multiple organs.
Though our findings may not be generalisable to SLE patients in all countries or healthcare settings, they are consistent with previous, more limited assessments of pre-index use and costs in SLE. Two studies were conducted using primary care data from the UK Clinical Practice Research Datalink. In one, 17 the median number of primary care visits for SLE patients increased from six per year (Years -5, -4 and -3) to seven (Year -2), and 12 in the year before diagnosis. Conversely, visits for the non-SLE comparison group (median 3) were unchanged. 17 The second UK study 16 reported an increase in median annual consultations from one (4 to 4.5 years before diagnosis, IQR ¼ 0-17), to 23 in Year -2 (IQR ¼ 11-43), and 38 in Year -1 (IQR ¼ 23-61). A third study, conducted in Taiwan, 18 found that pre-index outpatient costs were significantly greater for SLE than non-SLE, even for eight years before diagnosis. The annual median number of ambulatory care encounters was significantly greater for SLE each year, and rose from 1 (Year -8) to 11 (Year -5), 13 Determined using a generalised estimating equations (count) model, with negative binomial distribution.
c Determined using two-part models: a logistic regression model for the odds of incurring non-zero costs, and generalised linear model with gamma distribution and log-link predicting costs for those with non-zero costs. SES: socioeconomic status; SLE: systemic lupus erythematosus.
(Year -2) and 22 in Year -1. 18 Similar findings on incremental pre-index costs have been reported for rheumatoid arthritis (RA) patients in Taiwan, 36 and psoriatic arthritis 37 and RA 38 patients in Denmark. In the latter study, costs for RA patients were significantly greater than the general populations', even 11 years before diagnosis.
Despite our having a publicly funded healthcare system covering all BC residents, we found that low SES was independently associated with increased healthcare costs, especially in the final two years before diagnosis. Specifically, the lowest SES group had greater outpatient costs than the highest SES, were more likely to be diagnosed in hospital, and incurred greater hospitalisation costs at diagnosis. Since there are no private acute-care hospitals in BC, these differences in hospitalisation rates and costs cannot be attributed to the highest-SES patients obtaining care outside the public system. It is possible, however, that the lowest-SES individuals face difficulties in accessing care that eventually land them in hospital at the time of diagnosis, requiring more complex care. Low household income has been associated with delayed presentation to rheumatology care among paediatric SLE patients in the USA, 39 something that warrants further exploration in adult SLE. However, it may be less of an issue within Canada's single-payer system, where access to primary and specialist care is more universal.
Another striking finding was SLE males having significantly higher costs than SLE females in this period, even after adjustment for age, urban/rural residence, and SES. Unlike the SES groups, males and females were quite similar regarding the sources of diagnosis; however, SLE males did have a significantly higher pre-index comorbidity burden than females. There is disagreement in the literature about whether males (particularly Caucasians) tend to be diagnosed at an older age than females, and have a different, perhaps more severe, form of lupus with associated increased mortality. 40 But it has been reported that males are more likely to have renal disease at SLE diagnosis, 9, 10 and accrue more organ damage than females. 10, 20 Evidence also suggests that, among those with confirmed SLE, cardiovascular disease/ damage is higher in males. [41] [42] [43] If males also have more organ damage and comorbidities in the preindex period, this may explain why pre-index healthcare costs were higher for males. Although costs in each pre-index year (and Year þ 1) were adjusted for the Charlson-Romano comorbidity score for the previous 365 days, there may have been residual differences in comorbidity burden between the sexes.
Though sex-specific data on pre-index comorbidities in SLE are not available, evidence does suggest that, overall, SLE patients have an increased inflammatory disease burden before diagnosis. In clinical studies, many patients have had nephritis 11, 12 or other forms of renal disease 9,10 at diagnosis, and while SLE patients are known to have an elevated risk of cardiovascular events immediately following diagnosis, 28 increased cardiovascular disease before SLE diagnosis has also been reported. Among members of the multinational Systemic Lupus International Collaborating Clinics (SLICC) cohort, prevalence of myocardial infarction around the time of SLE diagnosis (between five years before, and two years following) exceeded the figure reported for the general population (4.8% vs. 0.7%). 44 In a population-based study in rural Wisconsin, US, SLE patients had 3.8-times greater odds of cardiovascular disease in the two years prior to diagnosis, vs. a sex-and age-matched sample from the general population. This included three-times greater odds of both heart failure and ischaemic heart disease, and five-times greater odds of stroke. 8 Increased cardiovascular disease has also been observed in the years preceding diagnosis of RA 45, 46 and psoriatic arthritis, 37 and diabetes has been associated with subsequent diagnosis of RA. 47, 48 Several mechanisms have been proposed for the concurrence of SLE and these other inflammatory diseases. As mentioned by the SLICC investigators, early autoimmunity and early atherosclerosis may develop at the same time, but through independent processes; 44 alternatively, early subclinical autoimmunity may actually contribute to early subclinical atherosclerosis. 44 The Wisconsin investigators suggested that atherosclerosis may accelerate prior to full onset of SLE, but also acknowledged that formal diagnosis of SLE may have been delayed in their cohort due to its older age, rural nature, and higher percentage of males. 8 Renal disease, meanwhile, is likely an early manifestation of undiagnosed (or unconfirmed) SLE in itself.
We expect our novel estimates will inform current healthcare decision making, and efforts to expedite SLE diagnosis and treatment, or, in high-risk individuals, even prevent it from developing. One early or potentially pre-emptive treatment is HCQ. Persistent use of HCQ in newly diagnosed patients has been associated with a longer clinically quiescent phase, 49 and early initiation of HCQ (after initial symptoms, but before accumulation of ! four ACR criteria) has been shown to delay the accumulation of additional criteria. 21 Moreover, these efforts could be cost saving: A retrospective analysis of US commercial claims data 50 found that 'early' diagnosis of SLE (within six months of symptom onset) was associated with fewer flares, and lower levels of post-diagnosis healthcare costs, compared to those diagnosed 6-12 months after symptom onset. However, the possible harms and added costs of any early treatment efforts (including the consequences of treating false-positive cases of SLE) warrant careful evaluation.
Our administrative healthcare data imparted both strengths and limitations to this analysis. Although SLE patients were identified from ICD codes, and the diagnoses were not clinically confirmed, 86% were identified by a rheumatologist or hospitalisation, and our case definition has a reported specificity of 98% and positive predictive value of 91% in the Canadian setting. 31 Moreover, we helped ensure only truly incident SLE were included by requiring five years' pre-index followup time without meeting the case definition for SLE. As we did not have access to medical records, we could not assess whether the SLE index date coincided with patients' fulfilling at least four ACR classification criteria, but the temporal cost patterns we observed (costs rising in the final two years before diagnosis, and peaking the year after diagnosis) do lend support and are consistent with previous reports. 17, 18 Despite these limitations, our routinely collected data allowed us to identify virtually all newly diagnosed SLE patients in the province (regardless of age, employment, urban/rural residence, or disease severity) and capture their pre-index healthcare utilisation from all settings (not just primary care) with minimal selection and recall bias. Our estimates include the costs for all provincially funded outpatient encounters and hospitalisations, and virtually all community-dispensed prescriptions, regardless of age or funding. However, we acknowledge our estimates do not include items not captured in the databases (and not funded by the province) such as non-prescription medications and most allied health visits.
In this population-based analysis, the healthcare and economic impact of SLE was evident long before the diagnosis was recorded. Even in the fifth year before diagnosis, members of the SLE cohort were more likely to be hospitalised than non-SLE, and incurred greater direct medical costs: C$1131 more per person, on average. We hope this work will increase recognition of the early healthcare costs of SLE, including the impact of low SES and early comorbidities, and spur efforts to mitigate this burden.
